A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia.
Walter FiedlerJoerg ChromikStefanie AmbergMaxim KebenkoFelicitas TholVera SchlipfenbacherAnne Christine WilkeFranziska ModemannMelanie JanningHubert ServeArnold GanserCarsten BokemeyerSusann TheileUte DeppermannAnne L KranichMichael HeuserPublished in: British journal of haematology (2020)
Keyphrases
- phase ii study
- acute myeloid leukemia
- liver failure
- open label
- locally advanced
- respiratory failure
- acute lymphoblastic leukemia
- drug induced
- aortic dissection
- placebo controlled
- dendritic cells
- high dose
- diffuse large b cell lymphoma
- bone marrow
- hodgkin lymphoma
- multiple myeloma
- hepatitis b virus
- immune response
- low dose
- radiation therapy
- intensive care unit